While in lung adenocarcinoma, gastric cancer, hepatocellular carcinoma, melanoma, and pancreatic cancer, ANXA1 is upregulated and associated with poor prognosis [19–23]. This evidence concerns the gene ANXA1 and familial pancreatic carcinoma.